New therapies in chronic myelogenous leukemia.
| Family . | Examples . |
|---|---|
| Nucleoside analogues | Troxacitabine Clofarabine |
| Plant alkaloids | Homoharringtone |
| Hypomethylating agents | Decitabine |
| Farnesyl transferase inhibitors | R115777 SCH66336 |
| Arsenicals | Arsenic trioxide |
| Proteasome inhibitors | PS-341 |
| Antiangiogenic agents | Bevacizumab |
| Peptide vaccines | Bcr/Abl junction peptides PR1 |
| New kinase inhibitors | AG957 AG490 Adaphostin |
| New formulations of interferon-α | Polyethylene glycol (PEG)-interferon Pegasys Albuferon |
| Family . | Examples . |
|---|---|
| Nucleoside analogues | Troxacitabine Clofarabine |
| Plant alkaloids | Homoharringtone |
| Hypomethylating agents | Decitabine |
| Farnesyl transferase inhibitors | R115777 SCH66336 |
| Arsenicals | Arsenic trioxide |
| Proteasome inhibitors | PS-341 |
| Antiangiogenic agents | Bevacizumab |
| Peptide vaccines | Bcr/Abl junction peptides PR1 |
| New kinase inhibitors | AG957 AG490 Adaphostin |
| New formulations of interferon-α | Polyethylene glycol (PEG)-interferon Pegasys Albuferon |